Skip to main content

Table 1 Biodistribution of 3 H-FLT in mice bearing A431 tumors

From: Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

Tissue 3H-FLT uptake level ((%ID/g)×kg)
Control Gefitinib 100 Gefitinib 200
n = 8 n = 7 n = 7
Blood 0.088 ± 0.009 0.080 ± 0.017 0.091 ± 0.012
Tumor 0.589 ± 0.112 0.393 ± 0.093* 0.360 ± 0.059*
Muscle 0.093 ± 0.008 0.088 ± 0.013 0.094 ± 0.008
Heart 0.094 ± 0.012 0.085 ± 0.012 0.092 ± 0.008
Brown fat 0.082 ± 0.010 0.076 ± 0.006 0.083 ± 0.009
Lung 0.091 ± 0.012 0.085 ± 0.011 0.094 ± 0.007
Brain 0.016 ± 0.001 0.015 ± 0.001 0.015 ± 0.001
Spleen 0.115 ± 0.026 0.113 ± 0.025 0.122 ± 0.033
Liver 0.103 ± 0.014 0.100 ± 0.017 0.105 ± 0.012
Kidney 0.147 ± 0.016 0.132 ± 0.020 0.138 ± 0.014
Skin 0.089 ± 0.019 0.094 ± 0.009 0.092 ± 0.010
Tumor/muscle ratio 6.3 ± 1.3 4.6 ± 1.4* 3.8 ± 0.6*
  1. *p < 0.01 vs. Control.